Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
417
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry.

Hepatology communications·2025
Same author

Candidates for liver transplant evaluated at satellite clinics at a large academic transplant center are less likely to be waitlisted.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2024
Same author

The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study.

The American journal of gastroenterology·2024
Same author

Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2024
Same author

The delta in management of HDV/HBV coinfection: Lessons from a case.

Clinical liver disease·2024
Same author

Could the answer to NAFLD be hidden in diabetic therapy? The impact of T2DM treatment on NAFLD.

Clinical liver disease·2024

Related Experiment Video

Updated: Jun 24, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K

Autoimmune hepatitis: Current and future therapies.

Nancy S Reau1, Craig S Lammert2, Ethan M Weinberg3

  • 1Section of Hepatology, Hepatology Services, Rush University Medical Center, Chicago, Illinois, USA.

Hepatology Communications
|June 5, 2024
PubMed
Summary
This summary is machine-generated.

Autoimmune hepatitis (AIH) is a complex liver disease affecting many, with current treatments causing side effects. New, individualized, steroid-free approaches are crucial for better outcomes and reduced risks.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 24, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K

Area of Science:

  • Hepatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Autoimmune hepatitis (AIH) is a chronic, heterogeneous liver disease predominantly affecting women, potentially leading to cirrhosis and liver failure.
  • Current standard treatments involve immunosuppressants, but long-term use carries significant adverse effects.
  • The complex pathogenesis of AIH involves immune cell infiltration and inflammatory cascades, yet targeted therapies remain limited.

Purpose of the Study:

  • To highlight the challenges in advancing AIH treatment paradigms.
  • To emphasize the need for improved clinical trial designs and outcome assessments.
  • To advocate for individualized and steroid-free treatment strategies.

Main Methods:

  • Review of current understanding of AIH pathogenesis and treatment limitations.
  • Analysis of obstacles in clinical trial conduct, including patient recruitment and diversity.
  • Discussion of the need for defined outcomes and adaptive study designs.

Main Results:

  • Progress in AIH treatment has lagged behind other autoimmune diseases.
  • Clinical trials face significant hurdles, including patient diversity and outcome measurement.
  • Current treatment strategies lack personalization and contribute to steroid-related side effects.

Conclusions:

  • Individualized and steroid-free treatment approaches are essential for improving AIH prognosis.
  • Addressing challenges in clinical trials is critical for developing novel therapies.
  • Minimizing steroid-associated adverse effects is a key goal for enhancing patient quality of life.